PIA
OCUL icon

Piedmont Investment Advisors’s Ocular Therapeutix OCUL Stock Holding History

Piedmont Investment Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-560
Closed -$4K – 1878
2018
Q2 		$4K Buy
+560
New +$3.85K ﹤0.01% 2251

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Piedmont Investment Advisors's OCUL Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Ocular Therapeutix (OCUL) in Q3 2018, closing a stake of 560 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in OCUL in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 73 funds tracked by Wall St. Rank hold OCUL as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Ocular Therapeutix position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 560 Ocular Therapeutix shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Ocular Therapeutix in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Ocular Therapeutix position peaked at $4K in Q2 2018.
  • 73 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.